Notes to Unaudited Condensed Consolidated Financial Statements
For the Three Months Ended March 31, 2018 and 2017
1.
|
GENERAL ORGANIZATION AND BUSINESS
|
Boston Therapeutics, Inc. (the “Company”)
was formed as a Delaware corporation on August 24, 2009 under the name Avanyx Therapeutics, Inc. On November 10, 2010, the Company
entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Boston Therapeutics, Inc., a New Hampshire
corporation (“BTI”) providing for the merger of BTI into the Company with the Company being the surviving entity (the
“Merger”), the issuance by the Company of 4,000,000 shares of common stock to the stockholders of BTI in exchange for
100% of the outstanding common stock of BTI, and the change of the Company’s name to Boston Therapeutics, Inc. On February
12, 2018, the Company acquired CureDM Group Holdings LLC (“CureDM”), for 47,741,140
shares of common stock
of which 25,000,000 were delivered at closing and 22,741,140 shall be delivered in four equal tranches
of 5,685,285 each upon the achievement of specific milestones. See Note 3
The Company’s primary business is
the development, manufacture and commercialization of therapeutic drugs with a focus on complex carbohydrate chemistry to address
unmet medical needs in diabetes and inflammatory diseases. We have brought one product, SUGARDOWN®, to market and have begun
to make initial sales. We are currently focused on the development of two additional drug products: BTI-320, a non-systemic, non-toxic,
tablet for reduction of post-meal blood glucose in people living with diabetes that is fully developed, and IPOXYN, an injectable
anti-necrosis, anti-hypoxia drug that we are currently developing. Due to the lack of adequate funding, the Company has not done
any work with respect to IPOXYN to date.
The accompanying financial statements have
been prepared assuming the Company will continue as a going concern. The Company has limited cash resources, recurring cash used
in operations and operating losses history. As shown in the accompanying financial statements, the Company has an accumulated deficit
of approximately $22.5 million as of March 31, 2018 and used cash in operations of approximately $210,553 during the three months
ended March 31, 2018. These factors among others, raise substantial doubt about the Company’s ability to continue as a going
concern.
The Company has incurred recurring operating
losses since inception as it has worked to bring its SUGARDOWN
®
product to market and develop BTI-320 and IPOXYN. Management
expects such operating losses will continue until such time that substantial revenues are received from SUGARDOWN
®
or
the regulatory and clinical development of BTI-320 or IPOXYN is completed. The Company has approximately $205,000 cash on hand
at March 31, 2018. Management is currently seeking additional capital through private placements and public offerings of its common
stock. In addition, the Company may seek to raise additional capital through public or private debt or equity financings as well
as collaboration activities in order to fund our operations. The Company raised $275,000 in gross proceeds from private placements
of our Series A Preferred Stock during the first quarter of 2018. See Note 8. Management anticipates that cash resources will be
sufficient to fund our planned operations into the second quarter of 2018. The future of the Company is dependent upon its ability
to obtain continued financing and upon future profitable operations from the partnering, development and clarity of its new business
opportunities.
There can be no assurance that we will
be successful in accomplishing our objectives. Without such additional capital, we may be required to cease operations. The accompanying
financial statements do not include any adjustments that might result should the Company be unable to continue as a going concern.
2.
|
SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES
|
Basis of Presentation
The financial statements have been prepared
in conformity with accounting principles generally accepting in the United States of America (“US GAAP”).
Principles of Consolidation
The Condensed Consolidated Financial Statements
include the Company and its wholly-owned subsidiary, CureDM Group Holdings LLC (“CureDM”). All significant inter-company
transactions are eliminated in consolidation.
Use of Estimates
The preparation of financial statements
in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Boston Therapeutics, Inc.
Notes to Unaudited Condensed Consolidated
Financial Statements
For the Three Months Ended March 31, 2018
and 2017
Cash and Cash Equivalents
For purposes of reporting within the statement
of cash flows, the Company considers all cash on hand, cash accounts not subject to withdrawal restrictions or penalties, and all
highly liquid investments with original maturities of 90 days or less at the time of acquisition to be cash equivalents. The Company
maintains its cash in institutions insured by the Federal Deposit Insurance Corporation.
Revenue Recognition
The Company generates revenues from sales
of SUGARDOWN®. Revenue is recognized when there is persuasive evidence that an arrangement exists, the price is fixed and determinable,
the product is shipped in accordance with the customers’ Free On Board (FOB) shipping point terms and collectability is reasonably
assured. In practice, the Company has not experienced or granted significant returns of product. Shipping fees charged to customers
are included in revenue and shipping costs are included in costs of sales.
The Company generates revenue from royalties
pursuant to a licensing and manufacturing agreement, whereby the licensee sells and distributes territory licensed products, excluding
those manufactured and supplied by the Company in the territory. Revenue is recognized when there is persuasive evidence that an
arrangement exists, the price is fixed and determinable, the product is shipped and collectability is reasonably assured. No royalty
revenue was recognized during the three month periods ended March 31, 2018 or 2017.
Accounts Receivable
Accounts receivable is stated at the amount
management expects to collect from outstanding balances. Management establishes a reserve for doubtful accounts based on its assessment
of the current status of individual accounts. Balances that remain outstanding after management has used reasonable collection
efforts are written off against the allowance. There were no allowances for doubtful accounts as of March 31, 2018 and 2017.
Inventory
Inventory consists of raw materials, work-in-process
and finished goods of SUGARDOWN®. Inventories are stated at the lower of cost (weighted average cost method) or market, not
in excess of net realizable value. The Company adjusts the carrying value of its inventory for excess and obsolete inventory. The
Company continues to monitor the valuation of its inventory.
Intangible Assets
Intangible assets consist of identifiable finite-lived assets
acquired in business acquisitions. Acquired intangible assets are recorded at fair value on the date of acquisition and are amortized
over their economic useful lives on a straight line basis.
Goodwill
The Company follows the guidance of Financial
Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 350,
Goodwill and Other Intangible Assets
. Under
ASC 350, goodwill and certain other intangible assets with indefinite lives are not amortized, but instead are reviewed for impairment
at least annually.
As the Company operates its business in
one operating segment and one reporting unit, the Company’s goodwill is assessed at the Company level for impairment in the
fourth quarter of each year or more frequently if events or changes in circumstances indicate that impairment may exist. The Company
has the option to first assess qualitative factors to determine whether it is necessary to perform the two-step impairment test.
If the Company’s qualitative assessment reveals that goodwill impairment is more likely than not, the Company performs the
two-step impairment test. Alternatively, the Company may bypass the qualitative test and initiate goodwill impairment testing with
the first step of the two-step goodwill impairment test.
During the first step of the goodwill impairment
test, the Company compares the fair value of the reporting unit to its carrying value, including goodwill. If the fair value of
a reporting unit exceeds its carrying value, then the Company concludes that no goodwill impairment has occurred. If the carrying
value of the reporting unit exceeds its fair value, the Company performs the second step of the goodwill impairment test to measure
possible goodwill impairment loss. If the carrying value of the reporting unit’s goodwill exceeds its implied fair value,
then we would record an impairment loss equal to the difference.
The Company performed its impairment review
of goodwill for the years ended December 31, 2017 and 2016 and concluded that no impairment existed.
Boston Therapeutics, Inc.
Notes to Unaudited Condensed Consolidated
Financial Statements
For the Three Months Ended March 31, 2018
and 2017
Impairment of Long-lived Assets
The Company reviews long-lived assets,
which include the Company’s intangible assets, for impairment whenever events or changes in business circumstances indicate
that the carrying amounts of the assets may not be fully recoverable. Future undiscounted cash flows of the underlying assets are
compared to the assets’ carrying values. Adjustments to fair value are made if the sum of expected future undiscounted cash
flows is less than book value. To date, no adjustments for impairment have been made.
Loss per Share
Basic net loss per share is computed based
on the net loss for the period divided by the weighted average actual shares outstanding during the period. Diluted net loss per
share is computed based on the net loss for the period divided by the weighted average number of common shares and common equivalent
shares outstanding during each period unless the effect of such common equivalent shares would be anti-dilutive. Common stock equivalents
represent the dilutive effect of the assumed exercise of certain outstanding stock options using the treasury stock method. The
weighted average number of common shares for the three month period ended March 31, 2018 did not include 9,594,000, 46,179,669
and 40,406,713 for options, warrants and shares to be issued upon conversion of notes payable, respectively, because of their anti-dilutive
effect. The weighted average number of common shares for the three month period ended March 31, 2017 did not include 60,227,273,
and 12,094,000 and 28,404,669 for convertible notes payable and accrued interest, options and warrants, respectively, because of
their anti-dilutive effect.
Fair Value of Financial Instruments
Fair values determined by Level 1 inputs
utilize observable data such as quoted prices in active markets. Fair values determined by Level 2 inputs utilize data points other
than quoted prices in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs
utilize unobservable data points in which there is little or no market data, which require the reporting entity to develop its
own assumptions. The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, accounts
payable, accrued expenses, and notes payable. The carrying value of cash and cash equivalents, accounts receivable, accounts payable
and accrued expenses approximates fair value due to their short-term nature using level 3 inputs as defined above. The carrying
value of the notes payable as of March 31, 2018 and December 31, 2017, evaluated using level 3 inputs defined above based on quoted
market prices on rates available to the Company for debt with similar terms and maturities, approximates the fair value.
Convertible Instruments
U.S. GAAP requires companies to bifurcate
conversion options from their host instruments and account for them as free standing derivative financial instruments according
to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative
instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument
that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable
generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument
with the same terms as the embedded derivative instrument would be considered a derivative instrument. An exception to this rule
is when the host instrument is deemed to be conventional, as that term is described under applicable ASC 480-10.
When the Company has determined that the
embedded conversion options should not be bifurcated from their host instruments, the Company records, when necessary, discounts
to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between
the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price
embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date
of redemption.
Common Stock Purchase Warrants and Other
Derivative Financial Instruments
The Company classifies as equity any contracts
that (i) require physical settlement or net-share settlement or (ii) provide the Company with a choice of net-cash settlement or
settlement in its own shares (physical settlement or net-share settlement) providing that such contracts are indexed to the Company’s
own stock. The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement
to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or (ii) gives the
counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company
assesses classification of its common stock purchase warrants and other free standing derivatives at each reporting date to determine
whether a change in classification between assets and liabilities is required.
Boston Therapeutics, Inc.
Notes to Unaudited Condensed Consolidated
Financial Statements
For the Three Months Ended March 31, 2018
and 2017
The Company’s free standing derivatives
consisted of warrants to purchase common stock that were issued in connection with the issuance of debt and of embedded conversion
options with senior convertible debentures. The Company evaluated these derivatives to assess their proper classification in the
balance sheet as of March 31, 2018 using the applicable classification criteria enumerated under ASC 815-Derivatives and Hedging.
The Company determined that certain embedded conversion and/or exercise features do not contain fixed settlement provisions. The
convertible debentures contain a conversion feature such that the Company could not ensure it would have adequate authorized shares
to meet all possible conversion demands.
As such, the Company was required to record
the debt and warrant derivatives which do not have fixed settlement provisions as liabilities and mark to market all such derivatives
to fair value at the end of each reporting period.
Stock-Based Compensation
Stock–based compensation, including
grants of employee and non-employee stock options and modifications to existing stock options, is recognized in the income statement
based on the estimated fair value of the awards
.
The Company recognizes the compensation cost of share-based awards on a
straight-line basis over the requisite service period, which is generally the vesting period of the award.
The determination of the fair value of
share-based payment awards utilizing the Black-Scholes model is affected by the stock price and a number of assumptions, including
expected volatility, expected life, risk-free interest rate and expected dividends. The Company has a limited history of market
prices of its common stock and as such volatility is estimated using historical volatilities of similar public entities. The expected
life of the awards is estimated based on the simplified method. The risk-free interest rate assumption is based on observed interest
rates appropriate for the terms of our awards. The dividend yield assumption is based on history and expectation of paying no dividends.
Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from
those estimates. Stock-based compensation expense is recognized in the financial statements on a straight-line basis over the requisite
service period, based on awards that are ultimately expected to vest.
The Company grants stock options to non-employee
consultants from time to time in exchange for services performed for the Company. Equity instruments granted to non- employees
are subject to periodic revaluation over their vesting terms. In general, the options vest over the contractual period of the respective
consulting arrangement and, therefore, the Company revalues the options periodically and records additional compensation expense
related to these options over the remaining vesting period.
Recent Accounting Pronouncements
There are various updates recently issued,
most of which represented technical corrections to the accounting literature or application to specific industries and are not
expected to have a material impact on the Company’s financial position, results of operations or cash flows.
Reclassification
Certain amounts in the March 31, 2017 financial
statements have been reclassified to conform to the presentation used at March 31, 2018.
On February 12, 2018, the Company
entered into a Contribution Agreement, with the members of CureDM Group Holdings, LLC, a limited liability
company (“CureDM Group”), all of which except five are accredited investors (“CureDM Group Members”) pursuant
to which the CureDM Group Members agreed to contribute 100% of the outstanding securities of CureDM Group in exchange for an aggregate
of 47,741,140 shares of common stock of the Company (the “BTHE Contribution Shares”) of which 25,000,000 BTHE Contribution
Shares were delivered at closing and 22,741,140 BTHE Contribution Shares (the “Milestone BTHE Shares”) shall be delivered
in four equal tranches of 5,685,285 BTHE Contribution Shares each upon the achievement of specific milestone s (the “CureDM
Group Contribution”). The closing of the CureDM Group Contribution occurred on February 12, 2018.
Boston Therapeutics, Inc.
Notes to Unaudited Condensed Consolidated
Financial Statements
For the Three Months Ended March 31, 2018
and 2017
A summary of consideration is as follows:
25,000,000 shares of the Company's common stock
|
|
$
|
1,250,000
|
|
22,741,140 contingency shares of the Company’s common stock
|
|
|
1,137,057
|
|
|
|
|
|
|
Total consideration
|
|
$
|
2,387,057
|
|
|
|
|
|
|
The following summarizes the current estimates of fair value of assets acquired and liabilities assumed:
|
|
|
|
|
|
|
|
|
|
Assets acquired:
|
|
|
|
|
Cash
|
|
$
|
3,592
|
|
Property and equipment
|
|
|
273
|
|
Goodwill
|
|
|
2,313,277
|
|
Intangibles
|
|
|
234,122
|
|
Liabilities assumed:
|
|
|
|
|
Accounts payable and accrued expenses
|
|
|
(164,207
|
)
|
Net assets acquired
|
|
$
|
2,387,057
|
|
The
purchase price allocation for the above acquisition is subject to further refinement as management completes its assessment of
the valuation of certain assets and liabilities.
The
Company accounts for acquisitions in accordance with the provisions of ASC 805-10. The Company assigns to all identifiable assets
acquired a portion of the cost of the acquired net assets equal to the estimated fair value of such assets at the date of acquisition.
The Company records the excess of the cost of the acquired net assets over the sum of the amounts assigned to identifiable assets
acquired as goodwill. (See Note 11)
The
Company accounts for and reports acquired goodwill under Accounting Standards Codification subtopic 350-10, Intangibles-Goodwill
and Other (“ASC 350-10”). In accordance with ASC 350-10, at least annually, the Company tests its intangible assets
for impairment or more often if events and circumstances warrant. Any write-downs will be included in results from operations.
Pro
forma results
The
following table sets forth the unaudited pro forma results of the Company as if the acquisition of CureDM had taken place on the
first day of the period presented. These combined results are not necessarily indicative of the results that may have been achieved
had the companies been combined as of the first day of the period presented. (See Note 11)
|
|
Three months
ended,
March 31, 2018
|
|
|
Three months
ended,
March 31, 2017
|
|
|
|
|
|
|
|
|
|
Total revenues
|
$
|
9,236
|
|
|
$
|
4,479
|
|
Net loss
|
|
(2,743,206)
|
|
|
|
(828,607
|
)
|
Basic and diluted net earnings per common share
|
$
|
(0.03)
|
|
|
$
|
(0.01
|
)
|
This pro forma financial information is based on historical
results of operations, adjusted for the allocation of the purchase price and other acquisition accounting adjustments, and is not
indicative of the results that may have been achieved had the companies been combined as of the first day of the period presented.
Boston Therapeutics, Inc.
Notes to Unaudited Condensed Consolidated
Financial Statements
For the Three Months Ended March 31, 2018
and 2017
Inventory consist of material, labor and
manufacturing overhead and are recorded at the lower of cost, using the weighted average cost method, or net realizable value.
The components of inventory at March 31, 2018 and December 31, 2017, net of inventory reserves, were as follows:
|
|
2018
|
|
|
2017
|
|
Raw materials
|
|
$
|
33,055
|
|
|
$
|
33,055
|
|
Finished goods
|
|
|
3,765
|
|
|
|
5,486
|
|
Total
|
|
$
|
36,820
|
|
|
$
|
38,541
|
|
The Company periodically reviews quantities
of inventory on hand and compares these amounts to expected usage of each particular product or product line. The Company records,
as a charge to cost of sales, any amounts required to reduce the carrying value to net realizable value.
The SUGARDOWN® technology and patent
applications, which were obtained through the acquisition of BTI in 2010, are being amortized on a straight-line basis over their
estimated useful lives of 14 years. The BTI-420 technology and patent applications, which were obtained through the acquisition
of CureDM in 2018, are being amortized on a straight-line basis over their estimated useful lives of 5 years.
Intangible assets consist of the following at March 31, 2018
and December 31, 2017:
|
|
2018
|
|
|
2017
|
|
SUGARDOWN® technology and patent applications
|
|
$
|
1,819,827
|
|
|
$
|
900,000
|
|
Less accumulated amortization
|
|
|
(1,186,337
|
)
|
|
|
(460,714
|
)
|
Intangible assets, net
|
|
$
|
633,490
|
|
|
$
|
439,286
|
|
Amortization expense was $39,918 and $16,071 for the three months
ended March 31, 2018 and 2017, respectively.
Boston Therapeutics, Inc.
Notes to Unaudited Condensed Consolidated
Financial Statements
For the Three Months Ended March 31, 2018
and 2017
6.
|
FAIR VALUE OF FINANCIAL INSTRUMENTS
|
The Company measures the fair value of
financial assets and liabilities based on the guidance of ASC 820 “Fair Value Measurements and Disclosures” which defines
fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 defines
fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal
or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement
date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize
the use of unobservable inputs when measuring fair value.
ASC 820 describes three levels of inputs that may be used to
measure fair value:
Level 1 - quoted prices in active markets for identical
assets or liabilities
Level 2 - quoted prices for similar assets and liabilities
in active markets or inputs that are observable
Level 3 - inputs that are unobservable based on an entity’s own assumptions,
as there is little, if any, related market activity (for example, cash flow modeling inputs based on assumptions)
Financial liabilities as of March 31, 2018
measured at fair value on a recurring basis are summarized below:
|
|
March 31,
2018
|
|
|
Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)
|
|
|
Significant
Other
Observable
Inputs
(Level 2)
|
|
|
Significant
Unobservable
Inputs
(Level 3)
|
|
Derivative liability
|
|
$
|
336,013
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
336,013
|
|
Warrant liability
|
|
|
2,554,736
|
|
|
|
—
|
|
|
|
—
|
|
|
|
2,554,736
|
|
Total
|
|
$
|
2,890,749
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
2,890,749
|
|
Financial liabilities as of December 31,
2017 measured at fair value on a recurring basis are summarized below:
|
|
December 31,
2017
|
|
|
Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)
|
|
|
Significant
Other
Observable
Inputs
(Level 2)
|
|
|
Significant
Unobservable
Inputs
(Level 3)
|
|
Derivative liability
|
|
$
|
429,141
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
429,141
|
|
Warrant liability
|
|
|
1,099,200
|
|
|
|
—
|
|
|
|
—
|
|
|
|
1,099,200
|
|
Total
|
|
$
|
1,528,341
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,528,341
|
|
The Company determined that certain conversion/exercise
option related to a convertible note and issued warrants did not have fixed settlement provisions and are deemed to be derivative
financial instruments, since the conversion/exercise prices was subject to reset adjustment should the Company issue any option
to acquire the Company’s common stock lower than the conversion /exercise price. Accordingly, the Company was required to
record such conversion/exercise options as a liability and mark such derivative to fair value each reporting period. Such instrument
was classified within Level 3 of the valuation hierarchy.
Boston Therapeutics, Inc.
Notes to Unaudited Condensed Consolidated
Financial Statements
For the Three Months Ended March 31, 2018
and 2017
The fair value of the conversion/exercise
options were calculated using a binomial lattice formula with the following weighted average assumptions during the three months
ended March 31, 2018 and the year ended December 31, 2017:
Conversion option:
|
|
March 31,
|
|
|
December 31,
|
|
|
|
2018
|
|
|
2017
|
|
Common Stock Closing Price
|
|
$
|
0.078
|
|
|
$
|
0.04 to 0.07
|
|
Conversion Price per Share
|
|
$
|
0.075 to 0.10
|
|
|
$
|
0.075 to 0.10
|
|
Conversion Shares
|
|
|
7,666,666
|
|
|
|
21,666,667
|
|
Call Option Value
|
|
|
0.0395to 0.0556
|
|
|
|
0.0188 to 0.0568
|
|
Dividend Yield
|
|
|
0.00
|
%
|
|
|
0.00
|
%
|
Volatility
|
|
|
218.89
|
%
|
|
|
208.82% to 214.34
|
%
|
Risk-free Interest Rate
|
|
|
1.73% to 2.09
|
%
|
|
|
1.03% to 1.76
|
%
|
Term
|
|
|
0.37 to 1.07 years
|
|
|
|
0.62 to 2 years
|
|
Exercise option:
|
|
March 31,
|
|
|
December 31,
|
|
|
|
2018
|
|
|
2017
|
|
Common Stock Closing Price
|
|
$
|
0.078
|
|
|
$
|
0.04 to 0.075
|
|
Conversion Price per Share
|
|
$
|
0.10 to 0.15
|
|
|
$
|
0.10 to 0.15
|
|
Conversion Shares
|
|
|
29,000,000
|
|
|
|
29,000,000
|
|
Call Option Value
|
|
|
0.0454 to 0.0764
|
|
|
|
0.0375 to 0.0723
|
|
Dividend Yield
|
|
|
0.00
|
%
|
|
|
0.00
|
%
|
Volatility
|
|
|
218.89
|
%
|
|
|
208.82 to 214.34
|
%
|
Risk-free Interest Rate
|
|
|
2.33 to 2.56
|
%
|
|
|
1.62 to 2.2
|
%
|
Term
|
|
|
3.37 to 4.98 years
|
|
|
|
3.62 to 5 years
|
|
The risk-free interest rate is the United
States Treasury rate on the measurement date having a term equal to the remaining contractual life of the instrument. The volatility
is a measure of the amount by which the Company’s share price has fluctuated or is expected to fluctuate. The dividend yield
is 0% as the Company has not made any dividend payment and has no plans to pay dividends in the foreseeable future. Level 3 liabilities
are valued using unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of
the derivative liabilities. For fair value measurements categorized within Level 3 of the fair value hierarchy, the Company’s
Chief Financial Officer, who reports to the Chief Executive Officer, determine its valuation policies and procedures. The development
and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility
of the Company’s Chief Financial Officer and are approved by the Chief Executive Officer. Level 3 financial liabilities consist
of the derivative liabilities for which there is no current market for these securities such that the determination of fair value
requires significant judgment or estimation. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy
are analyzed each period based on changes in estimates or assumptions and recorded as appropriate. Significant observable and unobservable
inputs include stock price, exercise price, annual risk free rate, term, and expected volatility, and are classified within Level
3 of the valuation hierarchy. An increase or decrease in volatility or interest free rate, in isolation, can significantly increase
or decrease the fair value of the derivative liabilities. Changes in the values of the derivative liabilities are recorded as a
component of other income (expense) on the Company’s statements of operations.
Boston Therapeutics, Inc.
Notes to Unaudited Condensed Consolidated
Financial Statements
For the Three Months Ended March 31, 2018
and 2017
The following table sets forth a summary
of the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring
basis using significant unobservable input for the three months ended March 31, 2018:
|
|
Debt
|
|
|
Warrant
|
|
|
|
Derivative
|
|
|
Liability
|
|
Balance, December 31, 2017
|
|
$
|
429,141
|
|
|
$
|
1,099,200
|
|
Aggregate amount of derivative instruments issued
|
|
|
—
|
|
|
|
226,833
|
|
Transferred in due to conversions
|
|
|
(273,080
|
)
|
|
|
—
|
|
Change in fair value of derivative liabilities
|
|
|
179,952
|
|
|
|
1,228,703
|
|
Balance, March 31, 2018
|
|
$
|
336,013
|
|
|
$
|
2,554,736
|
|
7.
|
CONVERTIBLE NOTES PAYABLE
|
In August and September 2016, the Company
issued senior convertible debentures for an aggregate of $1,600,000 (the “Convertible Debentures”) in exchange for
an aggregate net cash proceeds of $1,327,300, net of financing costs. The Convertible Debentures have a stated interest rate of
6% per annum payable quarterly beginning June 30, 2017 and are due two years from the date of issuance, the latest due September
15, 2018 and are convertible into shares of the Company’s common stock at the option of the holder at a conversion price
of $0.075 with certain anti-dilutive (reset) provisions and are subject to forced conversion if either i) the volume weighted average
common stock price for each of any 10 consecutive trading days equals or exceeds $0.50, or (ii) the Company’s elects to lists
a class of securities on a national securities exchange.
As long as the convertible notes remain
outstanding, the Company is restricted from incurring any indebtedness or liens, except as permitted (as defined), amend its charter
in any matter that materially effects rights of noteholders, repay or repurchase more than de minimis number of shares of common
stock other than conversion or warrant shares, repay or repurchase all or any portion of any indebtedness or pay cash dividends.
In connection with the issuance of the
Convertible Debentures, the Company issued an aggregate of 16,000,000 warrants to purchase the Company’s common stock at
$0.10 per share, expiring five years from the date of issuance, the latest being September 15, 2021. These warrants contain a cashless
exercise and certain anti-dilutive (reset) provisions.
The Company determined that certain conversion/exercise
option related to a convertible note and issued warrants did not have fixed settlement provisions and are deemed to be derivative
financial instruments due to price protection features present in the conversion/ exercise price that are not consistent with a
fixed for fixed model.
The accounting treatment of derivative
financial instruments requires that the Company record the fair value of the derivative as of the issuance date of the debenture
and warrants and to re-measure the derivatives at fair value as of each subsequent reporting date.
The Company recognized the value attributable
to the conversion feature of the convertible debenture and issued warrants of $2,203,336 and together with financing costs of $272,700
(aggregate of $2,476,036) as a discount against the notes up to $1,600,000 with the excess of $876,036 charged to current period
interest. The Company valued the conversion option and the warrants using the Binomial Lattice pricing model as described in Note
6. The debt discount is amortized over the note’s maturity period as interest expense.
On April 11, 2017, one investor converted
his Convertible Debenture of $75,000 plus accrued interest of $2,873, into 1,038,301 shares of the Company’s common stock.
Upon conversion, a loss on extinguishment was recorded in the amount of $51,267.
On July 14, 2017, one investor converted
his Convertible Debenture of $50,000 plus accrued interest of $2,482, into 711,755 shares of the Company’s common stock.
Upon conversion, a loss on extinguishment was recorded in the amount of $30,274.
During the first three months of 2018,
20 investors converted their Convertible Debentures totaling $1,050,000 plus accrued interest of $41,784, into 14,557,116 shares
of the Company’s common stock. Upon conversion, a loss on extinguishment was recorded in the amount of $257,775.
Boston Therapeutics, Inc.
Notes to Unaudited Condensed Consolidated
Financial Statements
For the Three Months Ended March 31, 2018
and 2017
For the three months ended March 31, 2018
and 2017, the Company amortized $275,841 and $197,260, respectively, of debt discount to operations as interest expense.
Convertible notes
payable consist of the following at March 31, 2018 and December 31, 2017:
|
|
2018
|
|
|
2017
|
|
Principal balance
|
|
$
|
697,700
|
|
|
$
|
1,475,000
|
|
Debt discount
|
|
|
(77,450
|
)
|
|
|
(189,175
|
)
|
Deferred finance costs
|
|
|
(47,118
|
)
|
|
|
(78,534
|
)
|
Outstanding, net of debt discount
|
|
$
|
573,132
|
|
|
$
|
1,207,291
|
|
The Company is authorized to issue up to
5,000,000 shares of its $0.001 par value preferred stock and up to 200,000,000 shares of its $0.001 par value common stock. During
the year ended December 31, 2013, the Company amended its certificate of incorporation to increase the number of common shares
from 100,000,000 to 200,000,000. The amendment went into effect September 7, 2013.
On January 9, 2018, the Company’s
Board of Directors voted to approve an increase in authorized common stock from 200 million shares to 2 billion shares of the Company’s
common stock. This increase was approved by the shareholders in the first quarter of 2018.
Series A Preferred Stock
The Company has designated 150,000 shares
of its preferred stock as Series A Preferred Stock. Each share of Series A Preferred Stock has a stated value of $10. The Series
A Preferred Stock is convertible into shares of the Company’s common stock by dividing the stated value by a conversion price
of $0.10 per share. The Series A Preferred Stock shall have voting rights on an as converted basis (subject to limitations) and
liquidation preference for each share of Series A Preferred Stock at an amount equal to the stated value per share. As of March
31, 2018, the Company has 82,500 shares of Series A Preferred Stock outstanding.
On August 14, 2017, the Company entered
into Securities Purchase Agreements with two accredited investors. In connection with these agreements, the Company issued 45,000
shares of Series A Preferred Stock and warrants to acquire 9,000,000 shares of common stock. The shares of Series A Preferred Stock
are convertible, at any time at the option of the holder, into an aggregate of 4,500,000 shares of the Company’s common stock.
The Warrants shall be exercisable for a period of five years at an exercise price of $0.15 per share.
The Company recognized the value attributable
to the conversion feature of the issued warrants of $650,421 as a charge against additional paid in capital up to $450,000 with
the excess of $200,421 charged to change in fair value of warrant liability during the year ended December 31, 2017. The Company
valued the warrants using the Binomial Lattice pricing model as described in Note 6.
On October 24, 2017, the Company entered
into Securities Purchase Agreements with an accredited investor. In connection with the agreement, the Company issued 10,000 shares
of Series A Preferred Stock and warrants to acquire 2,000,000 shares of common stock. The shares of Series A Preferred Stock are
convertible, at any time at the option of the holder, into an aggregate of 1,000,000 shares of the Company’s common stock.
The Warrants shall be exercisable for a period of five years at an exercise price of $0.15 per share.
The Company recognized the value attributable
to the conversion feature of the issued warrants of $93,312 as a charge against additional paid in capital. The Company valued
the warrants using the Binomial Lattice pricing model as described in Note 6.
On February 2, 2018, the Company entered
into Securities Purchase Agreements with four accredited investors. In connection with these agreements, the Company issued 27,500
shares of Series A Preferred Stock and warrants to acquire 5,500,000 shares of common stock in consideration of $275,000. The shares
of Series A Preferred Stock are convertible, at any time at the option of the holder, into an aggregate of 2,750,000 shares of
the Company’s common stock. The Warrants shall be exercisable for a period of five years at an exercise price of $0.15 per
share.
Boston Therapeutics, Inc.
Notes to Unaudited Condensed Consolidated
Financial Statements
For the Three Months Ended March 31, 2018
and 2017
The Company recognized the value attributable
to the conversion feature of the issued warrants of $226,833 as a charge against additional paid in capital. The Company valued
the warrants using the Binomial Lattice pricing model as described in Note 6.
Common Stock
On February 16, 2018, the Company’s
Board of Directors approved the issuance of 3,666,666 shares of the Company’s common stock to two consultants for services
rendered amounting to $330,000.
During the first three months of 2018, 20 investors converted
their Convertible Debenture totaling $1,050,000 plus accrued interest of $41,784, into 14,557,116 shares of the Company’s
common stock.
Common Stock Warrants
The Company accounts for warrants as either
equity instruments or liabilities depending on the specific terms of the warrant agreement. As of March 31, 2018, the Company had
46,179,669 warrants outstanding which are all classified as equity instruments and are fully exercisable.
The following table summarizes the Company’s
common stock warrants activity for the three months ended March 31, 2018:
|
|
|
Warrants
|
|
|
Weighted
Average
Exercise
Price
|
|
|
Aggregate Intrinsic Value
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding as of December 31, 2017
|
|
|
|
41,029,669
|
|
|
|
0.23
|
|
|
$
|
—
|
|
Granted
|
|
|
|
5,500,000
|
|
|
|
0.15
|
|
|
|
—
|
|
Exercised
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Forfeited/Canceled
|
|
|
|
(350,000
|
)
|
|
|
1.00
|
|
|
|
—
|
|
Outstanding as of March 31, 2018
|
|
|
|
46,179,669
|
|
|
|
0.22
|
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The aggregate intrinsic value represents the pretax intrinsic
value, based on the warrants with an exercise price less than the Company’s stock price of $0.08 as of March 31, 2018, which
would have been received by the warrant holders had those warrant holders exercised their warrants as of that date.
9.
|
STOCK OPTION PLAN AND STOCK-BASED COMPENSATION
|
During the year ended December 31, 2010,
the Company adopted a stock option plan entitled “The 2010 Stock Plan” (2010 Plan) under which the Company may grant
options to purchase up to 5,000,000 shares of common stock. On September 7, 2013, the 2010 plan was amended to increase the number
of shares of common stock issuable under the 2010 Plan to 7,500,000. As of March 31, 2018 and December 31, 2017, there were 250,000
and 250,000 options outstanding under the 2010 Plan, respectively.
During the year ended December 31, 2011,
the Company adopted a non-qualified stock option plan entitled “2011 Non-Qualified Stock Plan” (2011 Plan) under which
the Company may grant options to purchase 2,100,000 shares of common stock. In December 2012, the 2011 Plan was amended to increase
the number of shares of common stock issuable under the 2011 Plan to 12,000,000 shares. During the period ended March 31, 2013,
the 2011 Plan was amended to increase the number of shares of common stock issuable under the 2011 Plan to 17,500,000. As of March
31, 2018 and December 31, 2017, there were 13,344,000 and 9,344,000 options outstanding under the 2011 Plan, respectively
Under the terms of the stock plans, the
Board of Directors shall specify the exercise price and vesting period of each stock option on the grant date. Vesting of the options
is typically three to four years and the options typically expire in five to ten years.
Boston Therapeutics, Inc.
Notes to Unaudited Condensed Consolidated
Financial Statements
For the Three Months Ended March 31, 2018
and 2017
On February 12, 2018, Loraine Upham was
appointed as Chief Operating Officer. Ms. Upham received a stock option to purchase 4,000,000 shares of common stock under the
Company’s Amended and Restated 2011 Stock Incentive Plan, vesting over three (3) years, one third on the first anniversary
of the effective date and the balance in equal quarterly installments. The exercise price of the initial tranche of options (1,333,334
shares) shall be $0.06 per share, the second tranche (1,333,333 shares) shall be $0.10 per share and the final tranche (1,333,333
shares) shall be $0.20 per share. The term of the options is five years.
On March 1, 2018 the Board of Directors
approved a reduction in the exercise price of 6,000,000 stock options issued to the Company’s CEO on August 22, 2016. The
First tranche of 2,000,000 will be exercisable at $0.10 per share and the second and third tranches of 2,000,000 will be exercisable
at $0.15 per share. The remainder of the terms remain unchanged
No stock options were issued under either
plan during the three months ended March 31, 2017.
The fair value of stock options granted and revaluation of non-employee
consultant options for the three months ended March 31, 2018 was calculated with the following assumptions:
|
|
2018
|
|
Risk-free interest rate
|
|
|
2.3
|
%
|
Expected dividend yield
|
|
|
0
|
%
|
Volatility factor
|
|
|
217.6
|
%
|
Expected life of option
|
|
|
5 years
|
|
The weighted-average fair value of stock
options granted during the three months ended March 31, 2017 under the Black-Scholes option pricing model was $0.048. For the three
months ended March 31, 2018 and 2017, the Company recorded stock-based compensation expense of $46,281 and $12,439, respectively,
in connection with share-based payment awards. As of March 31, 2018 and 2017, there was $334,179 and $219,756, respectively of
unrecognized compensation expense related to non-vested stock option awards.
The following table summarizes the Company’s
stock option activity during the three months ended March 31, 2018:
|
|
Shares
|
|
|
Exercise
Price per
Share
|
|
|
Weighted
Average
Exercise Price
per Share
|
|
Outstanding as of December 31, 2017
|
|
|
9,594,000
|
|
|
|
$
|
|
|
|
0.10 – 1.21
|
|
|
$
|
0.36
|
|
Granted
|
|
|
4,000,000
|
|
|
|
|
|
|
|
0.06 – 0.20
|
|
|
|
0.12
|
|
Exercised
|
|
|
—
|
|
|
|
|
|
|
|
—
|
|
|
|
—
|
|
Options forfeited/cancelled
|
|
|
—
|
|
|
|
|
|
|
|
—
|
|
|
|
—
|
|
Outstanding as of March 31, 2018
|
|
|
13,594,000
|
|
|
|
$
|
|
|
|
0.06 – 1.21
|
|
|
$
|
0.29
|
|
Boston Therapeutics, Inc.
Notes to Unaudited Condensed Consolidated
Financial Statements
For the Three Months Ended March 31, 2018
and 2017
The following table summarizes information about stock options
that are vested or expected to vest at March 31, 2018:
|
|
|
|
Vested or Expected to Vest
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercisable Options
|
|
Exercise
Price
|
|
|
Number of
Options
|
|
|
Weighted
Average
Exercise Price
Per Share
|
|
|
Weighted
Average
Remaining
Contractual
Life (Years)
|
|
|
Aggregate
Intrinsic
Value
|
|
|
Number of
Options
|
|
|
Weighted
Average
Exercise
Price
Per Share
|
|
|
Weighted
Average
Remaining
Contractual
Life (Years)
|
|
|
Aggregate
Intrinsic
Value
|
|
$
|
0.06
|
|
|
|
1,333,334
|
|
|
$
|
0.06
|
|
|
|
4.88
|
|
|
$
|
24,000
|
|
|
|
—
|
|
|
$
|
0.06
|
|
|
|
4.88
|
|
|
$
|
—
|
|
|
0.10
|
|
|
|
2,933,333
|
|
|
|
0.10
|
|
|
|
6.55
|
|
|
|
—
|
|
|
|
1,600,000
|
|
|
|
0.10
|
|
|
|
6.55
|
|
|
|
—
|
|
|
0.18
|
|
|
|
934,000
|
|
|
|
0.18
|
|
|
|
5.23
|
|
|
|
—
|
|
|
|
934,000
|
|
|
|
0.18
|
|
|
|
5.23
|
|
|
|
—
|
|
|
0.20
|
|
|
|
3,483,333
|
|
|
|
0.20
|
|
|
|
4.12
|
|
|
|
—
|
|
|
|
2,150,000
|
|
|
|
0.20
|
|
|
|
4.12
|
|
|
|
—
|
|
|
0.37
|
|
|
|
58,000
|
|
|
|
0.37
|
|
|
|
4.43
|
|
|
|
—
|
|
|
|
58,000
|
|
|
|
0.37
|
|
|
|
4.43
|
|
|
|
—
|
|
|
0.40
|
|
|
|
2,000,000
|
|
|
|
0.40
|
|
|
|
3.42
|
|
|
|
—
|
|
|
|
—
|
|
|
|
0.40
|
|
|
|
3.42
|
|
|
|
—
|
|
|
0.42
|
|
|
|
63,000
|
|
|
|
0.42
|
|
|
|
2.75
|
|
|
|
—
|
|
|
|
63,000
|
|
|
|
0.42
|
|
|
|
2.75
|
|
|
|
—
|
|
|
0.50
|
|
|
|
310,000
|
|
|
|
0.50
|
|
|
|
1.58
|
|
|
|
—
|
|
|
|
310,000
|
|
|
|
0.50
|
|
|
|
1.58
|
|
|
|
—
|
|
|
0.60
|
|
|
|
2,000,000
|
|
|
|
0.60
|
|
|
|
3.42
|
|
|
|
—
|
|
|
|
—
|
|
|
|
0.60
|
|
|
|
3.42
|
|
|
|
—
|
|
|
0.69
|
|
|
|
100,000
|
|
|
|
0.69
|
|
|
|
6.00
|
|
|
|
—
|
|
|
|
100,000
|
|
|
|
0.69
|
|
|
|
6.00
|
|
|
|
—
|
|
|
1.21
|
|
|
|
379,000
|
|
|
|
1.21
|
|
|
|
5.78
|
|
|
|
—
|
|
|
|
379,000
|
|
|
|
1.21
|
|
|
|
5.78
|
|
|
|
—
|
|
$
|
0.06-1.21
|
|
|
|
13,594,000
|
|
|
$
|
0.29
|
|
|
|
4.59
|
|
|
$
|
24,000
|
|
|
|
5,594,000
|
|
|
$
|
0.27
|
|
|
|
5.22
|
|
|
$
|
—
|
|
The following table sets forth the status of the Company’s
non-vested stock options as of March 31, 2018 and December 31, 2017:
|
|
|
Number of
Options
|
|
|
Weighted-
Average
Grant-Date
Fair Value
|
|
Non-vested as of December 31, 2017
|
|
|
|
4,000,000
|
|
|
$
|
0.50
|
|
Granted
|
|
|
|
4,000,000
|
|
|
|
0.12
|
|
Forfeited
|
|
|
|
—
|
|
|
|
—
|
|
Vested
|
|
|
|
—
|
|
|
|
—
|
|
Non-vested as of March 31, 2018
|
|
|
|
8,000,000
|
|
|
$
|
0.31
|
|
Boston Therapeutics, Inc.
Notes to Unaudited Condensed Consolidated
Financial Statements
For the Three Months Ended March 31, 2018
and 2017
The
weighted-average remaining contractual life for options exercisable at March 31, 2018 is 5.22 years. At March 31, 2018 the Company
has 4,156,000 and 7,250,000 options available for grant under the 2011 Plan and 2010 Plan, respectively.
The
aggregate intrinsic value for fully vested, exercisable options was $24,000 at March 31, 2018. The aggregate intrinsic value of
options exercised during the three months ended March 31, 2018 was $0 as no options were exercised. The actual tax benefit realized
from stock option exercises during the three months ended March 31, 2018 was $0 as no options were exercised.
|
10
.
|
RELATED PARTY TRANSACTIONS
|
Through
December 31, 2011, a founder of the company and significant shareholder, Dr. David Platt advanced $257,820 to the Company to fund
start-up costs and operations. Advances by Dr. Platt carry an interest rate of 6.5% and were due on June 29, 2013. On May 7, 2012,
Dr. Platt and the Company’s former President and also a significant shareholder entered into promissory notes to advance
to the Company an aggregate of $40,000. The notes accrue interest at 6.5% per year and were due June 30, 2013. The outstanding
notes of $297,820 were amended each year to extend the maturity dates. Effective June 30, 2015, the outstanding notes for Dr. Platt
were amended to extend the maturity dates to June 30, 2017. During 2017, the Company made principal payments totaling $20,000 to
the former President of the Company, reducing the total balance of the outstanding notes to $277,820. As of March 31, 2018, the
remaining notes to Dr. Platt are in default and are classified as current liabilities.
On June
24, 2011, the Company entered into a definitive Licensing and Manufacturing Agreement (the “Agreement”) with Advance
Pharmaceutical Company Ltd. (“Advance Pharmaceutical”), a Hong Kong-based privately-held company. Under terms of the
Agreement, the Company manufactures and supplies product in bulk for Advance Pharmaceutical. Advance Pharmaceutical is responsible
for the packaging, marketing and distribution of SUGARDOWN® in certain territories within Asia. In addition, APC is able to
purchase the SUGARDOWN product directly from the US manufacturer and sell it within APC’s distribution area. In these situations,
the Company is entitled to royalty payments from APC of 10% of the total sales price paid upon shipment of the product. Advance
Pharmaceutical, through a wholly owned subsidiary, has purchased an aggregate 1,799,800 shares of the Company’s common stock
in conjunction with the Company’s private placement offerings during the years ended December 31, 2012 and 2011. The shares
were purchased on the same terms as the other participants acquiring shares in the respective offerings. Conroy Chi-Heng Cheng
is a director of Advance Pharmaceutical and joined the Company’s Board in December 2013. No revenue was generated pursuant
to the Agreement for the three months ended March 31, 2018 or 2017.
In December
2013, the Board of Directors agreed to indemnify Dr. Platt for legal costs incurred in connection with an arbitration (now concluded)
initiated before the American Arbitration Association by Galectin Therapeutics, Inc. (formerly named Pro-Pharmaceuticals, Inc.)
for which Dr. Platt previously served as CEO and Chairman. Galectin sought to rescind or reform the Separation Agreement entered
into with Dr. Platt upon his resignation from Galectin to remove a $1.0 million milestone payment which Dr. Platt asserted he was
entitled to receive and to be repaid all separation benefits paid to Dr. Platt. The Company initially capped the amount for which
it would indemnify Dr. Platt at $150,000 in December 2013 and Dr. Platt agreed to reimburse the indemnification amounts paid by
the Company should he prevail in the arbitration. The Board decided to indemnify Dr. Platt after considering a number of factors,
including the scope of the Company’s existing indemnification obligations to officers and directors and the potential impact
of the arbitration on the Company. In May 2014, the Board approved a $50,000 increase in indemnification support, solely for the
payment of outside legal expenses. The Company recorded a total of $182,697 in costs associated with Dr. Platt’s indemnification,
of which $119,401 was expensed in the year ended December 31, 2013 and of which $63,296 was expensed in the year ended December
31, 2014. In July 2014, the arbitration was concluded in favor of Dr. Platt, confirming the effectiveness of the separation agreement
and payment was made to Dr. Platt in July 2014.
Boston Therapeutics, Inc.
Notes to Unaudited Condensed Consolidated
Financial Statements
For the Three Months Ended March 31, 2018
and 2017
On March
2, 2015, the Board of Directors voted to reduce the amount that Dr. Platt was required to reimburse the Company to $82,355 and
to offset this amount against interest accrued in respect of the outstanding note payable to Dr. Platt. In addition, the Board
determined that Dr. Platt would be charged interest related to the $182,697 indemnification payment since funds were received by
Dr. Platt in July 2014. The Board of Directors concluded the foregoing constituted complete satisfaction of Dr. Platt’s indemnification
by the Company. Accordingly, the Company recorded the reduction in accrued interest through equity during the year ended December
31, 2015. As of March 31, 2018 and December 31, 2017, $44,296 and $38,979, respectively, of accrued interest in connection with
the related party promissory notes, had been included in accrued expenses and other current liabilities on the accompanying balance
sheet.
During
September 2015, the Company entered into a securities purchase agreement with CJY. Pursuant to this agreement, the Company issued
to CJY a convertible promissory note in the principal amount of $750,000. The Note was amended during the fourth quarter of 2015
to $1,200,000. During 2016, the Note was amended to $1,752,000. This Note provided necessary bridge financing to the Company prior
to a financing of $1,600,000 completed in the third quarter of 2016. Interest accrues at the rate of 10% per annum and is due upon
maturity of the note in August 2018. The Company may prepay this Note and any accrued interest at any time. At any time amounts
outstanding under the CJY Note are convertible into the Company’s common stock, in whole or in part, at the option of the
lender, at a conversion price of $0.05 per share. A beneficial conversion feature of $1,642,000 was calculated and capped at the
value of the note pursuant to ASC 470 - 20. The Company recorded amortization of the beneficial conversion feature as interest
expense in the amount of $104,661 and $154,665 during the three month ended March 31, 2018 and 2017, respectively.
On October
6, 2017, in accordance with the terms of the Securities Purchase Agreement, CJY Holdings converted $500,000 of Notes in exchange
for 10,000,000 shares of the Company’s common stock. The cost basis for the shares issued was $0.05. Upon conversion, a loss
on extinguishment of $15,354 was charged to additional paid in capital.
On October
16, 2017, CJY holdings converted an additional $50,000 of the Notes along with $150,000 of accrued interest into 4,000,000 shares
of the Company’s common stock. The cost basis for the shares issued was $0.05. Upon conversion, a loss on extinguishment
of $155,459 was charged to additional paid in capital.
On
April 26, 2017,
Boston Therapeutics, Inc. (the “Company”)
entered into
Securities Purchase Agreement with CJY Holdings Limited (“CJY”) providing for the sale by the Company to CJY of 6%
Subordinated Convertible Debenture in an amount of up to $1,000,000 (the “Debentures”). In addition to the Debentures,
CJY will also receive stock purchase warrants (the “Warrants”) to acquire 500,000 shares of common stock of the Company
for every $50,000 in Debentures purchased. The Warrants are exercisable for five years at an exercise price of $0.10 and may be
exercised on a cashless basis. The Company may only use the proceeds for the payment of services or materials associated with clinical
trials. The Company closed on $200,000 in financing and issued the related Debentures and Warrants under this agreement on April
26, 2017.
Boston Therapeutics, Inc.
Notes to Unaudited Condensed Consolidated
Financial Statements
For the Three Months Ended March 31, 2018
and 2017
The
Debentures bear interest at 6% per annum and mature two years from issuance. CJY may elect to convert all or part of the Debentures,
plus accrued interest, at any time into shares of common stock of the Company at a conversion price of $0.10 per share. Interest
on the Debentures is payable in cash or shares of common stock at $0.10 per share quarterly commencing June 30, 2017. The conversion
price is subject to adjustment for stock dividends and stock splits. In addition, if after the original issue date of the Debentures,
either (i) the volume weighted average price equals or exceeds $0.50 for 10 consecutive trading days or (ii) the Company elects
to list a class of securities on a national securities exchange, the Company may cause CJY to convert all or part of the then outstanding
principal amount of the Debentures plus, accrued but unpaid interest, liquidated damages and other amounts owed.
CJY
agreed to restrict its ability to convert the Debentures and exercise the Warrants and receive shares of common stock such that
the number of shares of common stock held by CJY after such conversion or exercise does not exceed 4.99% of the then issued and
outstanding shares of common stock.
A beneficial
conversion feature of $186,939 was calculated and capped at the value of the note pursuant to ASC 470 - 20. The Company recorded
amortization of the beneficial conversion feature as interest expense in the amount of $23,560 during the three months ended March
31, 2018. In connection with this borrowing, the Company also issued warrants to purchase 2,000,000 shares of the Company’s
common stock at $0.10 per share.
Convertible notes
payable – related party consist of the following at March 31, 2018 and December 31, 2017:
|
|
2018
|
|
|
2017
|
|
Principal balance
|
|
$
|
1,402,000
|
|
|
$
|
1,402,000
|
|
Debt discount
|
|
|
(256,610
|
)
|
|
|
(384,857
|
)
|
Outstanding, net of debt discount
|
|
$
|
1,145,390
|
|
|
$
|
1,017,143
|
|
11.
|
COMMITMENTS AND CONTINGENCIES
|
Leases
The Company currently leases
office space at 354 Merrimack Street, Lawrence, MA 01843 on a month to month basis. The Company recognized rent expense of $900
during the three months ended March 31, 2018 and 2017, respectively. There are no future minimum lease payments as of March 31,
2018.
The Company also leases office
space on a month-to-month basis at The BioScience Center 5901 Indian School Rd., Albuquerque, NM 87110. The Company recognized
rent expense of $427 during the three months ended March 31, 2018. There are no future minimum lease payments as of March 31, 2018.
On
February 12, 2018, the Company entered into a Contribution Agreement , with the members of CureDM Group Holdings,
LLC, a limited liability company (“CureDM Group”), all of which except five are accredited investors (“CureDM
Group Members”) pursuant to which the CureDM Group Members agreed to contribute 100% of the outstanding securities of CureDM
Group in exchange for an aggregate of 47,741,140 shares of common stock of the Company (the “BTHE Contribution Shares”)
of which 25,000,000 BTHE Contribution Shares were delivered at closing and 22,741,140 BTHE Contribution Shares (the “Milestone
BTHE Shares”) shall be delivered in four equal tranches of 5,685,285 BTHE Contribution Shares each upon the achievement of
specific milestones
(the “CureDM Group Contribution”). The closing of the CureDM
Group Contribution occurred on February 12, 2018
.
The Company believe the milestones
noted above will be achieved and that the Milestone BTHE Shares will be issued. Therefore, the Company has established a contingent
liability to recognize the shares expected to be issued. The basis for the contingent liability shares obligation is at
$0.05 per share or $1,137,057 which is the fair value of the Company’s stock on the day of the closing. Contingent liability
at March 31, 2018 is $1,137,057.
Boston Therapeutics, Inc.
Notes to Unaudited Condensed Consolidated
Financial Statements
For the Three Months Ended March 31, 2018
and 2017
Employment Agreement
The Company entered into an
Employment Agreement with Carl W. Rausch pursuant to which Mr. Rausch was engaged as the Chief Executive Officer of the Company
for a period of three years. Mr. Rausch was initially required to relocate from Hong Kong to the United States. However, due to
his continued efforts in Hong Kong, the Company and Mr. Rausch, in March 2017, have amended the employment agreement to remove
the provision requiring Mr. Rausch to relocate to the United States. Mr. Rausch received a signing bonus of $60,000 and an annual
salary of $224,000, which will be increased to $264,000 upon Mr. Rausch relocating to the United States. Further, upon the Company
being listed on a national exchange, Mr. Rausch’s salary will be increased by $20,000. The Company granted Mr. Rausch a Stock
Option (the “Rausch Option”) to acquire an aggregate of 6,000,000 shares of common stock of the Company, exercisable
for five (5) years, subject to vesting. The Rausch Option shall be earned and vested in three equal tranches of 2,000,000 upon
the Company raising $1,000,000 in financing, the Company raising $5,000,000 in financing and the Company entering into a significant
corporate alliance for substantial marketing and selling of the Company’s product portfolio. The initial tranche shall be
exercisable at $0.20 per share, the second tranche will be $0.40 per share and the third tranche shall be $0.60 per share, which
such vesting is subject to Mr. Rausch’s continued employment as an executive with the Company as of the vesting date. In
addition, as additional consideration for Mr. Rausch’s commitment to the Company, the stock options previously granted to
Mr. Rausch shall be amended to extend the expiration date to the ten year anniversary of signing date and such options shall be
considered fully vested. Mr. Rausch shall be entitled to certain raises and milestones subject to the achievement of certain milestones
to be agreed upon. In the event the Employment Agreement is terminated prior to the expiration of the term by the Company without
cause or by Mr. Rausch with good reason, the Company shall pay Mr. Rausch an amount equal to Mr. Rausch’s accrued but unpaid
base salary and earned but unpaid bonus prior to the termination date, reimbursement for any reimbursable business expenses and
Mr. Rausch’s salary for a period of one year.
On March 1, 2018 the Board of
Directors approved a reduction in the exercise price of 6,000,000 stock options issued to the Company’s CEO on August 22,
2016. The First tranche of 2,000,000 will be exercisable at $0.10 per share and the second and third tranches of 2,000,000 will
be exercisable at $0.15 per share. The remainder of the terms remain unchanged.
On February 12, 2018, Loraine
Upham was appointed as Chief Operating Officer. The Company and Ms. Upham entered into an Executive Retention Agreement pursuant
to which Ms. Upham was engaged as Chief Operating Officer with an annual salary of $200,000. However, Ms. Upham’s salary
shall accrue until the Company has raised a minimum of $1,250,000. Ms. Upham is eligible for bonuses as determined by the Board
of Directors. These include a bonus of $20,000 is to be paid upon the Company successfully raising $1,250,000 through the sale
of equity; an annual performance bonus based on milestones related to clinical progress, partnering and fund raising success to
be established by the Board of Directors or the Compensation Committee, if in existence on an annual basis. In addition, Ms. Upham
received a stock option to purchase 4,000,000 shares of common stock under the Company’s Amended and Restated 2011 Stock
Incentive Plan, vesting over three (3) years, one third on the first anniversary of the effective date and the balance in equal
quarterly installments. The exercise price of the initial tranche of options (1,333,334 shares) shall be $0.06 per share, the second
tranche (1,333,333 shares) shall be $0.10 per share and the final tranche (1,333,333 shares) shall be $0.20 per share. The term
of the options is five years.
The Company has evaluated events and transactions
that occurred from March 31, 2018 through the date of the filing for possible disclosure and recognition in the financial statements.
On April 9, 2018, one of the 6% Convertible
Notes Payable totaling $25,000 plus accrued interest have been converted into 348,840 shares of the Company’s common stock.